Novo Nordisk A Fs reported DKK12.61B in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Ani Pharmaceuticals ANIP:US USD 30.08M 1.88M
Aurora Cannabis Inc ACB:CN CAD 45.04M 5.32M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Canopy Growth Corp WEED:CN CAD 125.74M 27.65M
Catalent CTLT:US USD 196M 30M
Corcept Therapeutics CORT:US USD 35.16M 2.65M
Eli Lilly And LLY:US USD 1.61B 10.9M
Endo International Ordinary Shares ENDP:US USD 192.46M 10.92M
GlaxoSmithKline GSK:LN GBP 1.97B 13M
Horizon Pharma HZNP:US USD 397.56M 658K
Lannett LCI:US USD 16.7M 9.06M
Merk MRK:US USD 2.47B 13M
Nektar Therapeutics NKTR:US USD 22.53M 1.09M
Novartis NOVN:VX USD 3.4B 185M
Novo Nordisk A Fs NVO:US DKK 12.61B 778M
Pacira Pharmaceuticals PCRX:US USD 61.28M 3.72M
Perrigo Ordinary Shares PRGO:US USD 281M 57.1M
Phibro Animal Health PAHC:US USD 54.96M 576K
Prestige Brands PBH:US USD 70.26M 3.59M
Supernus Pharmaceuticals SUPN:US USD 224.63M 124.15M
Teva Pharmaceutical Industries TEVA:US USD 777M 72M
Valeant Pharmaceuticals VRX:CN USD 661M 15M
Zoetis ZTS:US USD 501M 28M